<div>
  <ul>
    <li>
      <p>
        US-based AI pharmaceutical company, ReviR Therapeutics, has entered a research collaboration and option-to-license agreement with Chinese biotech company, Asieris Pharmaceuticals, to develop novel RNA-targeted therapeutics. The terms and financial details of the agreement have not been disclosed.
      </p>
    </li>
    <li>
      <p>
        The partnership will leverage ReviR&rsquo;s RNA modulation technologies, including BindeR and SpliceR, and Asieris&rsquo;s R&amp;D expertise in oncology drug discovery to develop novel therapeutics across multiple oncology targets.&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.prnewswire.com/news-releases/revir-therapeutics-and-asieris-pharmaceuticals-enter-into-agreement-to-discover-oncology-therapeutics-based-on-revirs-comprehensive-approach-to-rna-targeted-technologies-301741812.html">
      PR Newswire
    </a>
  </p>
</div>


All Updates

ReviR Therapeutics partners with Asieris Pharmaceuticals to develop novel oncology therapies

ReviR Therapeutics raises around USD 20 million in pre-Series A funding